|
ABOUT OUR FOUNDER
Pinaki R. Majhi, Ph.D. Email: [email protected] Office: (508) 659-7002 Mobile: (415)-260-4096 LinkedIn: https://www.linkedin.com/in/pinakimajhi/ Dr. Pinaki Majhi founded Unicus Pharmaceuticals in May 2017. Dr. Majhi is a highly experienced product development professional with strong background in pharmaceutical and colloid chemistry (23+ years of combined research and product development experience in US, Germany, and India). He has expertise in product development (concept-to-launch) including pre-formulation, formulation design & optimization, and scale-up of topical, oral, ophthalmic, and personal care products. He is skilled in formulation and characterization of semi-solid, suspension, and liquid dosage forms and designing novel drug delivery/platform technologies. Dr. Majhi was involved with 120+ product development, reformulation, scale-up or manufacturing projects related to personal skincare, Rx/OTC topical (dermatological, optic, and ophthalmic), Rx/OTC oral liquid (e.g. cold & cough products), oral liquid supplements, and other products. Prior to Unicus Pharmaceuticals, Pinaki held R&D & Technical Operations positions for several pharmaceutical and personal care companies including Denison Pharmaceuticals, Amneal Pharmaceuticals, PreCision Dermatology, Valeant Pharmaceuticals NA, Dow Pharmaceutical Sciences, and Assam Company Limited. At Denison Pharmaceuticals, Dr. Majhi has been instrumental in founding new R&D Division and CRO business and converting Denison from CMO to CDMO (Contract Development Manufacturing Organization). Dr. Majhi holds a Ph.D. degree in Chemistry (Colloids, Pharmaceuticals) from Jadavpur University (India) and received postdoctoral training on lipid (vesicles), protein and nucleic acid chemistry from several universities in Germany and USA including Martin Luther University of Halle-Wittenberg (Germany), Indiana University-Purdue University Indianapolis, and University of California San Francisco. He has published 65+ publications (including research articles, patents, conference abstracts, and a book chapter) so far. |
